Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Antibiotic treatment may ease symptoms of irritable bowel syndrome.

[No authors listed]

Mayo Clin Womens Healthsource. 2011 Jun;15(6):3. No abstract available.

PMID:
21540786
2.

[Effectiveness confirmed in studies. Intestine selective antibiotic reduces irritable bowel syndrome effectively].

Neumaier J.

MMW Fortschr Med. 2010 Oct 28;152(43):2 p following 43. German. No abstract available.

PMID:
21171472
3.
4.

Treatment of patients with irritable bowel syndrome.

Weinstock LB.

Am Fam Physician. 2007 Jan 1;75(1):31. No abstract available.

5.

Antibiotic may improve irritable bowel syndrome.

[No authors listed]

Mayo Clin Health Lett. 2007 Mar;25(3):4. No abstract available.

PMID:
17396340
6.

Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?

Purslow C.

Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):263. No abstract available.

PMID:
22816171
7.

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3.

8.

Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome.

Weinstock LB.

Dig Dis Sci. 2011 Nov;56(11):3389-90. doi: 10.1007/s10620-011-1889-2. No abstract available.

PMID:
21948355
9.

Rifaximin for the treatment of irritable bowel syndrome.

Cremonini F, Lembo A.

Expert Opin Pharmacother. 2012 Feb;13(3):433-40. doi: 10.1517/14656566.2012.651458. Epub 2012 Jan 18. Review.

PMID:
22251066
10.

The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.

Schey R, Rao SS.

Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):461-4. doi: 10.1586/egh.11.50. Review.

PMID:
21780893
11.

Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.

Nee J, Zakari M, Lembo AJ.

Expert Opin Pharmacother. 2015;16(18):2781-92. doi: 10.1517/14656566.2015.1101449. Epub 2015 Nov 11. Review.

PMID:
26558923
12.

Antibiotic therapy for the irritable bowel syndrome.

Tack J.

N Engl J Med. 2011 Jan 6;364(1):81-2. doi: 10.1056/NEJMe1011211. No abstract available.

13.

[Evidence-based therapy of irritable bowel syndrome. Intestine selective antibiotic relieves symptoms significantly].

[No authors listed]

MMW Fortschr Med. 2009 May 21;151(21):56-7. German. No abstract available.

PMID:
19537640
14.

[Irritable bowel syndrome].

Musch A.

Med Monatsschr Pharm. 2006 Oct;29(10):378-9. German. No abstract available.

PMID:
17058897
15.

Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea.

[No authors listed]

Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11. Review. No abstract available.

PMID:
26218792
16.

Drugs for irritable bowel syndrome.

[No authors listed]

Treat Guidel Med Lett. 2011 Jul;9(107):41-6. No abstract available.

PMID:
21701443
17.

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.

Meyrat P, Safroneeva E, Schoepfer AM.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1084-93. doi: 10.1111/apt.12087. Epub 2012 Oct 16.

18.

Antibiotic treatment of constipation-predominant irritable bowel syndrome.

Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, Amichai M.

Dig Dis Sci. 2014 Jun;59(6):1278-85. doi: 10.1007/s10620-014-3157-8. Epub 2014 May 1.

PMID:
24788320
19.

Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.

Collins BS, Lin HC.

J Pediatr Gastroenterol Nutr. 2011 Apr;52(4):382-6. doi: 10.1097/MPG.0b013e3181effa3b.

PMID:
21240023
20.

Rifaximin for irritable bowel syndrome without constipation.

Krause R, Zollner-Schwetz I, Valentin T.

N Engl J Med. 2011 Apr 14;364(15):1467; author reply 1468. doi: 10.1056/NEJMc1101839#SA1. No abstract available.

PMID:
21488771

Supplemental Content

Support Center